6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of July 2026

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on July 2, 2026, titled “Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial.”

The first five paragraphs of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923) and Form F-3 (333-291368), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

3

Exhibit99.1

PolyrizonAnnounces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Raanana,Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results from its biocompatibility evaluation program for its proprietary NASARIX^TM^ Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria.

The comprehensive evaluation program was designed in accordance with internationally recognized standards for biological safety assessment of medical devices, including the ISO 10993 series, FDA guidance, and applicable European regulatory requirements. The program was developed to assess the safety and biocompatibility profile of NASARIX^TM^, a drug-free mucoadhesive nasal spray intended to help reduce exposure to airborne allergens associated with seasonal allergic rhinitis.

The completed testing program evaluated key biological safety endpoints identified for the device, including:

In addition, long-term systemic toxicity was assessed through a toxicological risk assessment conducted in accordance with ISO 10993-17, demonstrating substantial safety margins across the product’s constituent materials under intended conditions of use.

The biocompatibility evaluation was based on the final NASARIX^TM^ product configuration and supported by extensive toxicological assessments of the formulation components, manufacturing processes, packaging materials, and intended patient exposure. According to the Biological Evaluation Plan, the product consists of well-characterized materials with established safety profiles and utilizes a manufacturing process designed to minimize biological risk.

“We are pleased to report the successful completion of the NASARIX^TM^ biocompatibility program,” said Tomer Izraeli, CEO of Polyrizon. “Achieving positive results across all required biological safety assessments represents a significant milestone in our development program and further supports the biocompatibility safety profile of NASARIX^TM^ as we continue advancing its clinical and regulatory pathway.”

The biocompatibility evaluation program was developed under a risk-management framework consistent with ISO 10993-1 and ISO 14971 and included assessment of physical and chemical characteristics, material safety data, toxicological literature, manufacturing controls, and endpoint-specific biological testing.

The successful completion of the biocompatibility program further strengthens the non-clinical package supporting NASARIX^TM^ and represents an important step toward potential commercialization of the product as a novel nasal barrier technology designed to help individuals suffering from seasonal allergies.

AboutNASARIX^TM^

NASARIX^TM^ is Polyrizon’s proprietary nasal spray designed to create a protective barrier within the nasal cavity, helping to prevent contact between inhaled allergens and the nasal mucosa. The product is being developed as a non-drug approach for the management of seasonal allergic rhinitis.

AboutPolyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM^, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

ForwardLooking Statements

Thispress release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Actof 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,”“plans,” “believes,” “seeks,” “estimates” and similar expressions or variations ofsuch words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when itdiscusses the the timing and progress of its clinical trials, advancing the clinical and regulatory pathway of NASARIX^TM^and the potential commercialization of NASARIX^TM^ as a novel nasal barrier technology designed to help individualssuffering from seasonal allergies. Forward-looking statements are not historical facts, and are based upon management’scurrent expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefsand projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs andprojections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-lookingstatements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results todiffer materially from those expressed in the forward-looking statements. For a more detailed description of the risks anduncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securitiesand Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Reporton Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speakonly as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflectactual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-lookinginformation except to the extent required by applicable securities laws. If the Company does update one or more forward-lookingstatements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to otherforward-looking statements. References and links to websites have been provided as a convenience, and the information contained onsuch websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-partywebsites.

Contacts:Michal EfratyInvestor [email protected]